Biocept traded at $1.17 this Friday August 12th, decreasing $0.03 or 2.50 percent since the previous trading session. Looking back, over the last four weeks, Biocept lost 19.38 percent. Over the last 12 months, its price fell by 70.75 percent. Looking ahead, we forecast Biocept to be priced at 1.02 by the end of this quarter and at 0.94 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Abbott 111.48 0.99 0.90% -9.41%
Becton, Dickinson and Co. 263.69 4.29 1.65% 6.85%
Biocept 1.17 -0.03 -2.50% -70.75%
Celldex Therapeutics 37.33 2.80 8.11% -14.62%
Plus Therapeutics, Inc. 0.53 0.003 0.61% -74.61%
Quest Diagnostics 140.55 -0.02 -0.01% -5.17%
General Electric 79.93 1.03 1.31% -23.82%
Illumina 208.33 -19.12 -8.40% -59.73%
Roche Holding 315.00 4.85 1.56% -14.39%
Thermo Fisher Scientific 603.21 10.67 1.80% 10.75%

Indexes Price Day Year
USND 13047 267.27 2.09% -11.98%

Biocept, Inc. is an early stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor nucleic acid, including circulating tumor deoxyribonucleic acid (ctDNA) and circulating tumor ribonucleic acid (ctRNA), assays using a standard blood sample or liquid biopsy. Its blood and cerebrospinal fluid (CSF) assays are intended to provide information to aid healthcare providers by identifying tumor cells associated with progression or metastasis and identifying specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy. The Company's Target-Selector CTC and molecular platforms provide both biomarker detection as well as monitoring capabilities and require only a patient blood sample or CSF sample to inform treatment decisions. It also offers sensitive polymerase chain reaction (PCR) based assay through Aegea Biotechnologies, Inc. (Aegea) for detecting the COVID-19 virus.